Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00350870 · ClinicalTrials.gov registry record · Phase 1

CBT With Disulfiram and Contingency Management

A Phase 1 study of Cocaine Abuse, sponsored by Yale University.

Completed
Registry status
Phase 1
Development phase
181
Enrollment target
1
Study location

NCT00350870: Completed Phase 1 study of Cocaine Abuse, sponsored by Yale University.

NCT00350870 is a Phase 1 study of Cocaine Abuse that has completed, run by Yale University. The registered enrollment target is 181 participants, below the 899-participant average among 9 other Cocaine Abuse trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00350870, a Phase 1 study of Cocaine Abuse, has completed, sponsored by Yale University.

COMPLETED
Registry status
Phase 1
Development phase
181 participants
Enrollment target
1
Study location

Study Summary

This is a study of four treatments for chronic cocaine use and may help study participants to control their drug use. All participants will receive weekly individual cognitive behavioral therapy (CBT).

Primary Outcome

Self-reports of substance use will be documented at each contact via the Substance Use Calendar. Similar to the Form-90 and the Time Line Follow-Back, which have been shown to be reliable and valid instruments for monitoring substance use and other outcomes in longitudinal studies202-204, the Substance Use Calendar allows a flexible, continuous evaluation of substance use on a daily basis.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG disulfiram
  • BEHAVIORAL Placebo plus Contingency Management
  • DRUG Disulfiram plus Contingency Management

Study Locations (1)

Connecticut

  • APT Foundation - New Haven

Trial Details

FieldValue
Enrollment Target 181 participants
Start Date 2005-04
Est. Completion 2010-12
Phase Phase 1
Yale University

1,492 total trials

What the finished NCT00350870 record still lists

NCT00350870 is an interventional study that assigns participants to a tested intervention. The registered 181 participants enrollment target is mid-sized for trials with a published cap, below the 899-participant average among 9 other Cocaine Abuse trials with a reported enrollment target (80% lower).

The record links to 1 condition, with Cocaine Abuse appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT00350870 reports a single indexed study location in Connecticut.

Frequently Asked Questions

What is clinical trial NCT00350870 about?

NCT00350870 is a clinical study titled "CBT With Disulfiram and Contingency Management". This is a study of four treatments for chronic cocaine use and may help study participants to control their drug use. All participants will receive weekly individual cognitive behavioral therapy (CBT).

What is the current status of trial NCT00350870?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 181 participants. The study started on 2005-04. Estimated completion is 2010-12.

What conditions does trial NCT00350870 study?

This clinical trial studies the following conditions: Cocaine Abuse.

What interventions are being tested in trial NCT00350870?

The interventions under investigation include: Placebo (DRUG), disulfiram (DRUG), Placebo plus Contingency Management (BEHAVIORAL), Disulfiram plus Contingency Management (DRUG).

Who is sponsoring clinical trial NCT00350870?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00350870 being conducted?

This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cocaine Abuse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00350870's enrollment target sits among peer trials

181 2nd of 9 the highest of 9 other Cocaine Abuse trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cocaine Abuse trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04578392 · 181 participants · NA

    MeSenteric SpAring Versus High Ligation Ileocolic Resection for the Prevention of REcurrent Crohn's DiseaSe (SPARES)

  • NCT05597891 · 181 participants · NA

    Endovascular Engineering ENGULF Study

  • NCT03897998 · 182 participants · Phase 2

    Neural Correlates of Hypoalgesia Driven by Observation

  • NCT04300556 · 182 participants · Phase 1

    A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00350870, the US trial registry maintained by the National Library of Medicine. NCT00350870 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.